The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for IXINITY® (Medexus), a recombinant factor replacement therapy to treat patients with hemophilia B. The new approval expands the product…
#block-recentonlineeducation {
display:none;
}
Aprende sobre la terapia de reemplazo de factoresUno de los tratamientos utilizados para algunos trastornos hemorrágicos es la terapia de reemplazo de factores. El siguiente vídeo en 3D muestra…
NBDF recently learned that Novo Nordisk now has 3,000 IU vial size of Rebinyn® back in stock. Rebinyn is the company's recombinant factor IX extended half-life therapy for the treatment of hemophilia B. It is indicated for the on-demand treatment…
The Pittsburgh Pirates are teaming up with Western PA Bleeding Disorders Foundation to help enrich the lives of those with bleeding disorders in Western Pennsylvania. $10 of each ticket sold will benefit the Western PA Bleeding Disorders Foundation…
.stack {
float: left;
margin: 0px 20px 0px 20px;
}
@media only screen and (max-width: 600px){
.stack {
float: none;
}
}
Speaker: Guy Young, MDRegister to join us and learn about treatment options for hemophilia A…
Government Relations Update – March 2024Federal: NBDF’s 2024 Washington Days was held March 6-8. NBDF is grateful to the more than 400 volunteer advocates from forty-four states who participated in the 231…
The HANDI Resources Center Team is pleased to announce new 2024 scholarship opportunities available for the bleeding disorders community!Kevin Child Scholarship (KCS)The KCS awards $1,000 to eligible individuals living in the U.S.…
Keeping Your Informed In a significant development within the gene editing arena, Intellia Therapeutics has announced its decision to opt out of a hemophilia B program, relinquishing control of CRISPR/Cas9-based gene editing…
Speakers: Samantha Carlson, LMSW, and Halli Benasutti, Ph.D.Join Samantha Carlson, LMSW Director of Research & Halli Benasutti, Ph.D., Director of Research Grants, as they outline the 2024 funding opportunities…
A new paper published in The Lancet Haematology journal includes data from the HOPE-B clinical trial program that is investigating the hemophilia B gene therapy etranacogene dezaparvovec – the product’s commercial name is Hemgenix® (CSL Behring).…